High-Purity 2-Pyridineboronic Acid (CAS: 197958-29-5): Synthesis, Applications, and Supplier Information

Discover the essential properties, synthesis routes, and critical applications of 2-Pyridineboronic Acid (CAS: 197958-29-5), a vital pharmaceutical intermediate. Learn why it's a preferred choice for Suzuki-Miyaura coupling and discover how to source this high-quality chemical from reliable manufacturers in China.

Get a Quote & Sample

Key Advantages of 2-Pyridineboronic Acid

Exceptional Purity for Pharmaceutical Applications

Our 2-Pyridineboronic Acid (CAS: 197958-29-5) boasts a purity of 97% min, making it ideal for stringent pharmaceutical intermediate requirements. This high purity ensures predictable reaction outcomes and facilitates the synthesis of active pharmaceutical ingredients (APIs).

Enabling Complex Organic Synthesis

As a key component in Suzuki-Miyaura cross-coupling reactions, this boronic acid derivative is instrumental in forming critical carbon-carbon bonds. It is widely utilized by R&D scientists and product formulators for creating novel biaryl and heterocyclic compounds.

Cost-Effective Sourcing from China

We offer competitive pricing for 2-Pyridineboronic Acid, making it an accessible and cost-effective option for procurement. By partnering with us, you gain access to a dependable supplier with a robust manufacturing capability for your bulk orders.

Applications of 2-Pyridineboronic Acid

Pharmaceutical Synthesis

This compound is a vital intermediate in the creation of new drug molecules and APIs, leveraging its reactivity in complex synthetic pathways.

Organic Synthesis

Facilitates the formation of carbon-carbon bonds through Suzuki-Miyaura cross-coupling, essential for constructing complex organic structures.

Building Block for Heterocycles

Used in the synthesis of various heterocyclic compounds that are fundamental to many biologically active molecules.

Drug Discovery & Development

An indispensable reagent for R&D scientists exploring new therapeutic agents and chemical entities.